{"id":"oral-hypoglycemic-agents","safety":{"commonSideEffects":[{"rate":"variable by agent class","effect":"Hypoglycemia"},{"rate":"variable by agent class","effect":"Gastrointestinal disturbances"},{"rate":"variable by agent class","effect":"Weight gain"},{"rate":"rare","effect":"Lactic acidosis (biguanides)"},{"rate":"rare","effect":"Hepatotoxicity (thiazolidinediones)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a broad drug class rather than a single agent, encompassing multiple mechanistic approaches: sulfonylureas and meglitinides stimulate pancreatic beta cells to release insulin; biguanides (metformin) reduce hepatic glucose production and improve peripheral insulin sensitivity; thiazolidinediones enhance insulin sensitivity in muscle and adipose tissue; and newer agents like DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors work through incretin enhancement or renal glucose excretion.","oneSentence":"Oral hypoglycemic agents lower blood glucose levels through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:20.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07472725","phase":"PHASE2","title":"A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-04","conditions":"Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT07436182","phase":"PHASE4","title":"Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-03-01","conditions":"Mitochondria, Metformin","enrollment":176},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT07377448","phase":"","title":"Insulin Use and Respiratory Muscle Strength in Type 2 Diabetes","status":"COMPLETED","sponsor":"Izmir Bakircay University","startDate":"2025-01-02","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":70},{"nctId":"NCT02648009","phase":"PHASE1","title":"Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2016-04","conditions":"Hypertension, Hypertrophy","enrollment":112},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT06149793","phase":"PHASE2, PHASE3","title":"SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2024-01-08","conditions":"Cystic Fibrosis-related Diabetes, Cystic Fibrosis","enrollment":8},{"nctId":"NCT07295223","phase":"PHASE3","title":"Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-12-30","conditions":"Acute Myocardial Infarction With ST Elevation","enrollment":44},{"nctId":"NCT01301833","phase":"PHASE3","title":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-02","conditions":"Type 2 Diabetes Mellitus","enrollment":462},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07172971","phase":"PHASE1","title":"Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Larry W. Markham","startDate":"2026-02-01","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":10},{"nctId":"NCT07294495","phase":"NA","title":"Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR","status":"NOT_YET_RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2026-01-07","conditions":"HCM - Hypertrophic Cardiomyopathy","enrollment":150},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT07279909","phase":"PHASE3","title":"Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hamdard University","startDate":"2024-03-09","conditions":"Diabetes Type 2, Diabetes Mellitus, Experimental, HbA1c","enrollment":500},{"nctId":"NCT07265037","phase":"NA","title":"Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Diabetes Mellitus, Type 2, Integrated Traditional Chinese Medicine and Western Medicine, Telemedicine","enrollment":10000},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT07209527","phase":"EARLY_PHASE1","title":"Truway Diagnostic Tools in Primary Care","status":"ENROLLING_BY_INVITATION","sponsor":"Truway Health, Inc.","startDate":"2025-10-01","conditions":"Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension","enrollment":200},{"nctId":"NCT06813274","phase":"PHASE2","title":"Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling","status":"NOT_YET_RECRUITING","sponsor":"Hejiang Ye","startDate":"2026-01-01","conditions":"Diabetes Mellitus, Diabetic Retinopathy, Cognitive Impairment","enrollment":160},{"nctId":"NCT04826692","phase":"PHASE3","title":"TEsting METformin Against Cognitive Decline in HD","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2022-04-11","conditions":"Huntington Disease","enrollment":60},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT04198857","phase":"NA","title":"Development and Testing of a Mobile Health Application for Management of Gestational Diabetes","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2021-10-18","conditions":"Diabetes, Gestational, Telemedicine","enrollment":220},{"nctId":"NCT03608163","phase":"PHASE4","title":"Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2019-01-08","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":4},{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":"In-stent Restenosis","enrollment":252},{"nctId":"NCT07074379","phase":"NA","title":"Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-07-21","conditions":"Painless Chronic Pancreatitis","enrollment":126},{"nctId":"NCT06649773","phase":"PHASE3","title":"The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-10-25","conditions":"Type 2 Diabetes","enrollment":137},{"nctId":"NCT06846138","phase":"NA","title":"Enhancing the Efficacy and Tolerability of Metformin by add-on Polyherbal Formulation: a Gut Microbiome Study","status":"ENROLLING_BY_INVITATION","sponsor":"Pauls Stradins Clinical University Hospital","startDate":"2025-03-01","conditions":"Diabetes Mellitus Type 2","enrollment":66},{"nctId":"NCT07049601","phase":"NA","title":"THE Effect of Tight Glycemic Control on Microvascular Complications in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-05-11","conditions":"Diabetes Mellitus","enrollment":80},{"nctId":"NCT06562582","phase":"PHASE4","title":"STunning in Acute Myocardial Infarction - BAS","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-01-06","conditions":"Myocardial Infarct","enrollment":120},{"nctId":"NCT04841096","phase":"PHASE3","title":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2023-03-21","conditions":"Type 2 Diabetes","enrollment":162},{"nctId":"NCT06719661","phase":"NA","title":"The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"University of Sulaimani","startDate":"2024-12-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":138},{"nctId":"NCT01242202","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":113},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT06668389","phase":"PHASE4","title":"Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-05-12","conditions":"Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF), Pulmonary Regurgitation","enrollment":106},{"nctId":"NCT06932874","phase":"PHASE4","title":"Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-03-04","conditions":"Atherosclerotic Heart Disease, Type 2 Diabetes","enrollment":356},{"nctId":"NCT06929169","phase":"PHASE2","title":"Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study","status":"RECRUITING","sponsor":"Maximo Agustin Schiavone","startDate":"2025-05","conditions":"Chronic Kidney Disease Requiring Hemodialysis","enrollment":80},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":"Glomerulonephritis, Immunoglobulin A Nephropathy","enrollment":878},{"nctId":"NCT06862180","phase":"NA","title":"Effect of Meal Replacement Therapy on Glucose Control and Metabolic Parameters in Patients With Uncontrolled Diabetes","status":"RECRUITING","sponsor":"Hospital Universiti Sains Malaysia","startDate":"2024-11-01","conditions":"Diabetes Mellitus, Type 2","enrollment":108},{"nctId":"NCT04409795","phase":"PHASE2, PHASE3","title":"Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2021-08-26","conditions":"Type 1 Diabetes, Monogenic Diabetes","enrollment":3},{"nctId":"NCT06825182","phase":"PHASE3","title":"Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-11-07","conditions":"Type 2 Diabetes Mellitus","enrollment":1000},{"nctId":"NCT04114136","phase":"PHASE2","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-09-14","conditions":"Melanoma, NSCLC, Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT05055804","phase":"NA","title":"The ELG Analysis of Glucose a Correlational to Blood Glucose Assay","status":"ENROLLING_BY_INVITATION","sponsor":"XP Technology, LLC","startDate":"2021-08-11","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT06746610","phase":"NA","title":"Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2022-08-01","conditions":"Monogenic Diabetes","enrollment":2000},{"nctId":"NCT04813146","phase":"NA","title":"Role of Synchronized Lifestyle Modification Program on Diabetic Neuropathy Taking Oral Hypoglycemics","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2021-02-05","conditions":"Diabetic Neuropathies","enrollment":216},{"nctId":"NCT01672762","phase":"PHASE3","title":"A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-05-25","conditions":"Type 2 Diabetes Mellitus","enrollment":174},{"nctId":"NCT03418779","phase":"PHASE2, PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":"IgA Nephropathy at High Risk of Developing ESRD","enrollment":60},{"nctId":"NCT04342819","phase":"PHASE2, PHASE3","title":"The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.","status":"COMPLETED","sponsor":"The University of The West Indies","startDate":"2020-01-01","conditions":"Platelet Dysfunction Due to Drugs","enrollment":25},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06517602","phase":"NA","title":"Effect of Moringa Oleifera Leaves on Glycemic Control of Women With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Milan","startDate":"2019-11-07","conditions":"Type 2 Diabetes","enrollment":52},{"nctId":"NCT06510270","phase":"NA","title":"Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Aswan University","startDate":"2024-08-01","conditions":"Heart Failure with Preserved Ejection Fraction","enrollment":70},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT04809220","phase":"PHASE3","title":"A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","enrollment":591},{"nctId":"NCT06398977","phase":"NA","title":"Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients","status":"RECRUITING","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2024-03-11","conditions":"Peritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 Inhibitors","enrollment":70},{"nctId":"NCT05162014","phase":"","title":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":494679},{"nctId":"NCT06370247","phase":"NA","title":"First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-04-25","conditions":"SGLT2 Inhibitors, First Time Use, Type2 Diabetes, Fasting in Ramadan","enrollment":60},{"nctId":"NCT05976152","phase":"PHASE3","title":"Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04","conditions":"Stroke, Post-stroke Cognitive Impairment (PSCI)","enrollment":3200},{"nctId":"NCT06350487","phase":"PHASE4","title":"The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-05-01","conditions":"Heart Failure, Preserved Ejection Fraction","enrollment":154},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT05638880","phase":"PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2022-12-20","conditions":"Diabetic Nephropathies","enrollment":60},{"nctId":"NCT05335629","phase":"NA","title":"Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-06-01","conditions":"Myocardial Infarction, Diabetes Mellitus, Type 2, Myocardial Remodeling, Ventricular","enrollment":54},{"nctId":"NCT06203275","phase":"PHASE3","title":"The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"aya ramadan ashmawy sarhan","startDate":"2024-01","conditions":"Diabetes Mellitus, Type 2","enrollment":44},{"nctId":"NCT06191328","phase":"NA","title":"A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)","status":"UNKNOWN","sponsor":"Yufan Wang","startDate":"2024-01-31","conditions":"Diabetes","enrollment":40},{"nctId":"NCT05855863","phase":"PHASE4","title":"Clinical Study of GKT in Diabetes Related Dementia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2023-12-01","conditions":"Dementia","enrollment":370},{"nctId":"NCT05366868","phase":"PHASE4","title":"Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2022-05-26","conditions":"Diabetes Mellitus, Type 2","enrollment":567},{"nctId":"NCT06102720","phase":"PHASE4","title":"Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization","status":"UNKNOWN","sponsor":"Mikhail Zykov","startDate":"2023-01-12","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT06100796","phase":"","title":"Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-10-01","conditions":"Non Small Cell Lung Cancer Metastatic, Diabetes Mellitus","enrollment":60},{"nctId":"NCT05164523","phase":"","title":"The Effect of SGLT2 Inhibitors on Heart Rate Variability and BDNF Levels in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Goztepe Training and Research Hospital","startDate":"2021-03-01","conditions":"Type 2 Diabetes, Heart Rate Variability","enrollment":64},{"nctId":"NCT03877406","phase":"PHASE4","title":"Effect of Empagliflozin on Body Composition and Ketones","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-08-01","conditions":"Diabetes Mellitus, Fat; Intolerance, Pancreas","enrollment":200},{"nctId":"NCT05946148","phase":"","title":"Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2018-06-01","conditions":"Non-Alcoholic Fatty Liver Disease, Liver Steatosis","enrollment":78},{"nctId":"NCT04833413","phase":"","title":"Regimen Switch After Intensive Insulin Therapy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-04-15","conditions":"Insulin","enrollment":1000},{"nctId":"NCT05822674","phase":"","title":"Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2022-01-01","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT05624970","phase":"NA","title":"the Effect of Aerobic Training on Insulin Sensitivity on Diabetic Patients During Tobacco Cessation","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-11-09","conditions":"Diabetes","enrollment":60},{"nctId":"NCT05578352","phase":"NA","title":"The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT03798054","phase":"PHASE3","title":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-15","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT05417880","phase":"PHASE3","title":"Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus","status":"UNKNOWN","sponsor":"Scotmann Pharmaceuticals","startDate":"2022-08","conditions":"Diabetes Mellitus","enrollment":340},{"nctId":"NCT05310916","phase":"PHASE3","title":"Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Nidae Alaa","startDate":"2022-06-06","conditions":"Diabetic Retinopathy","enrollment":60},{"nctId":"NCT04907019","phase":"PHASE1","title":"A Drug Interaction Study of SY-004 Capsules in Healthy Subjects","status":"COMPLETED","sponsor":"Suzhou Yabao Pharmaceutical R&D Co., Ltd.","startDate":"2021-07-06","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT04907006","phase":"PHASE1","title":"A Food-drug Interaction Study of SY-004 in Healthy Subjects","status":"COMPLETED","sponsor":"Suzhou Yabao Pharmaceutical R&D Co., Ltd.","startDate":"2021-08-31","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT05359341","phase":"NA","title":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2020-09-20","conditions":"Diabete Type 2","enrollment":175},{"nctId":"NCT04155996","phase":"","title":"Data Acquisition Study in Inadequately Balanced Patients With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"ValoTec","startDate":"2019-01-20","conditions":"Type2 Diabetes","enrollment":10},{"nctId":"NCT03958591","phase":"PHASE4","title":"Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2019-05-01","conditions":"Diabetes type2","enrollment":274},{"nctId":"NCT03434119","phase":"PHASE3","title":"Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-02-20","conditions":"Type 2 Diabetes Mellitus","enrollment":241},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT05290506","phase":"PHASE3","title":"Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2020-08-01","conditions":"PreDiabetes, Type 2 Diabetes","enrollment":50},{"nctId":"NCT05145140","phase":"PHASE1","title":"A Clinical Intervention Study of Tangningtongluo on Diabetic Foot Ulcer","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-01-15","conditions":"Diabetic Foot Ulcer","enrollment":80},{"nctId":"NCT05262257","phase":"EARLY_PHASE1","title":"Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-04-01","conditions":"Type2 Diabetes","enrollment":120},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":"Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome","enrollment":43},{"nctId":"NCT04385589","phase":"PHASE4","title":"Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-05-01","conditions":"Heart Failure","enrollment":100},{"nctId":"NCT05241431","phase":"PHASE2, PHASE3","title":"Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2022-02-12","conditions":"Aortic Stenosis, Left Ventricle Hypertrophied","enrollment":106},{"nctId":"NCT05184049","phase":"PHASE4","title":"Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-01","conditions":"Diabetes","enrollment":72},{"nctId":"NCT05105698","phase":"PHASE1","title":"Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2022-01-01","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT04323462","phase":"PHASE4","title":"Intensive Glycemic Control For Diabetic Foot Ulcer Healing","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-01","conditions":"Diabetic Foot Ulcer","enrollment":326}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"BLOOD GLUCOSE FLUCTUATION"},{"count":2,"reaction":"DRUG INTERACTION"},{"count":2,"reaction":"HEPATITIS"},{"count":2,"reaction":"RHABDOMYOLYSIS"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ANGIOEDEMA"},{"count":1,"reaction":"BLOOD CREATINE INCREASED"},{"count":1,"reaction":"BLOOD POTASSIUM INCREASED"},{"count":1,"reaction":"BLOOD PRESSURE DIASTOLIC DECREASED"},{"count":1,"reaction":"CATAPLEXY"}],"_approvalHistory":[],"publicationCount":1962,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"oral hypoglycemic agents","genericName":"oral hypoglycemic agents","companyName":"Queen Elizabeth II Health Sciences Centre","companyId":"queen-elizabeth-ii-health-sciences-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral hypoglycemic agents lower blood glucose levels through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}